Dr. David Spigel from Sarah Cannon Cancer Center offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.

[powerpress]

We've covered a wide range of topics  in our "ASCO 2012 Lung Cancer Highlights" podcast series over the last few weeks.  This webinar and the podcasts from it featured Drs.

We've been producing a series of podcasts from our Lung Cancer Highlights from ASCO 2012 webinar, featuring Drs.

As part of our program on lung cancer highlights, Dr.

In my last post, I described the concept of treating with a targeted therapy like an EGFR tyrosine kinase inhibitor (TKI) or ALK inhibitor at the time of acquired resistance.

The annual conference of the American Society of Clinical Oncology in late spring is the biggest event in the cancer world, where more of the big trials are presented than at any other time all year.  In the lung cancer world, it’s looking like this one won’t be a blockbuster but will have some promising and interesting findings to dis

Here's the final piece of the webinar with our own Dr. Jared Weiss on Highlights in Lung Cancer from 2011 -- the question and answer session that followed his presentation.  Below is the transcript, figures, and the audio and video versions of the podcast.

Apologies for the long wait since our own Dr. Weiss's upbeat and thoughtful review of the leading stories about lung cancer in 2011.  Dr. Weiss covered a lot of ground in his presentation that was followed by a Q&A session, so we've broken that up into several short pieces that cover a few highlights at a time.

It was almost exactly a year ago that I described the basic results of the global LUX Lung-1 trial that enrolled 585 patients with advanced NSCLC who had gone at least 12 weeks without progression on Tarceva (erlotinib) or Iressa (gefitinib) in a 2:1 fashion to either the oral targeted therapy afatinib (an irreversible inhibitor of the human epidermal receptor (HER) family, of which EGFR

Here's the second talk from our recent webinar, partnering with LUNGevity Foundation to cover the ASCO Highlights in Lung Cancer, and this talk followed after